Cell-surface antigens of melanoma recognized by human monoclonal antibodies Academic Article Article uri icon


MeSH Major

  • Antigens, Neoplasm
  • Genetic Therapy
  • HLA-A2 Antigen
  • Immunologic Factors
  • Immunotherapy, Active
  • Interleukin-2
  • Melanoma
  • Recombinant Fusion Proteins
  • Tumor Cells, Cultured


  • Human monoclonal antibodies (mAbs) were derived from lymph node lymphocytes and peripheral blood lymphocytes (PBL) from patients with melanoma. Four methods for generating human mAbs were compared: fusion with human [LICR-LON-HMy-2 (LICR-2)] or mouse (NS-1) cells; transformation by Epstein-Barr virus (EBV); and EBV transformation followed by NS-1 fusion. NS-1 fusion with lymph node lymphocytes resulted in a higher number of growing hybrids than LICR-2 fusion. Virtually no hybrids were obtained from NS-1 or LICR-2 fusions with PBL. EBV transformed lymphocytes from lymph node and peripheral blood with equal efficiency, and the yield of proliferating cultures for antibody screening was more than 10- to 30-fold greater than that obtained by fusion techniques. However, once antibody-producing cultures had been identified, stability and clonability of EBV-transformed cells were poorer than that of NS-1 hybrid cells. To combine the strengths of both methods, cultures of EBV-transformed cells were fused with NS-1; and hybrid clones were isolated that showed vigorous growth, clonability, and stable antibody secretion. Detailed specificity analysis of the mAbs produced by six of these clones indicated detection of a class 1 (unique) melanoma antigen, a class 3 melanoma antigen, and four ganglioside antigens (GD3, GM3, and two other, as yet uncharacterized, heterophile antigens).

publication date

  • July 21, 1987



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1073/pnas.84.8.2416

PubMed ID

  • 3031684

Additional Document Info

start page

  • 2416

end page

  • 20


  • 84


  • 8